June 20, 2010
Therapeutic Potential Of Embryonic Stem Cells
Are stem cells ready for prime time?
The therapeutic potential of embryonic stem cells has been an intense focus of study and discussion in biomedical research and has resulted in technologies to produce human induced pluripotent stem cells (hiPSCs). Derived by epigenetic reprogramming of human fibroblasts, these hiPSCs are thought to be almost identical to human embryonic stem cells (hESCs) and provide great promise for patient-tailored regenerative medicine therapies. However, recent studies have suggested noteworthy differences between these two stem cell types which require additional comparative analyses.Scientists at Children's Memorial Research Center at Northwestern University Feinberg School of Medicine investigated the expression of key members of the Nodal embryonic signaling pathway, critical to maintaining pluripotency, in hiPSC and hESC cell lines. Nodal is an important morphogen "“ a soluble molecule that can regulate cell fate "“ in embryological systems that requires tight regulatory control of its biological function.
The group's results demonstrated slightly lower levels of Nodal and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitory regulator) in hiPSCs compared with hESCs, suggesting less regulatory control of cell fate in reprogrammed stem cells. Based on these findings, additional work addressed the implications associated with the epigenetic reprogramming of hiPSCs and examined a global comparative analysis of 365 microRNAs (miRs) in hiPSC vs. hESC lines.
The data revealed 10 highly expressed miRs in hiPSCs with greater than 10-fold difference, which have been shown to be cancer related. Collectively, these data demonstrate cancer hallmarks expressed by hiPSCs, which will require further elucidation for their impact on clinical applications, especially with respect to the fate of precancerous stem cells.
Entitled "Cancer hallmarks in induced pluripotent cells: new insights", this paper is published online in the Journal of Cellular Physiology. The authors are Sergey Malchenko, Vasil Galat (two first authors), Elisabeth A. Seftor, Elio F. Vanin, Fabricio F. Costa, Richard E.B. Seftor, Marcelo B. Soares and Mary J.C. Hendrix (two senior authors), Cancer Biology and Epigenomics Program (SM, EAS, EFV, FFC, REBS, MBS and MJCH) and Developmental Biology Program (VG). This research was supported by the National Cancer Institute (MJCH), the National Heart, Lung and Blood Institute (VG), the Maeve McNicholas Memorial Foundation (FFC), and the Medical Research Institute Council.
On the Net: